CBRNE - Plague
- Author: Susan E Dufel, MD, FACEP; Chief Editor: Duane C Caneva, MD, MSc more...
The plague has caused more fear and terror than perhaps any other infectious disease in the history of humankind. It has laid claim to nearly 200 million lives and has brought about monumental changes such as the end of the Dark Ages and the advancement of clinical research in medicine.
Although still debated by historians, the plague has been responsible for at least 3 great pandemics and multiple epidemics in history. The first spread occurred from the Middle East to the Mediterranean basin during the fifth and sixth centuries AD, killing approximately 50% of the population in these areas. The second pandemic afflicted Europe between the 8th and 14th centuries, destroying nearly 40% of the population. The third pandemic started in approximately 1855 in China, and, although it has been mostly controlled, it is still ongoing.
Alexandre Yersin isolated the plague bacillus, developed an antiserum to combat the disease, and postulated its connection with fleas and rats during the epidemic of 1894. The plague bacillus was named Yersinia pestis in his memory.
Pandemics have succeeded in entrenching the plague in every major continent, with the possible exception of Australia. Unlike smallpox, the plague never will be eradicated. It lives in millions of animals and on billions of fleas that reside on them. It is a disease of the desert, the steppes, the mountains, and the forest.
Although, the plague has been considered a disease of the Middle Ages, multiple outbreaks in India and Africa during the last 20 years have stoked fears of another global pandemic. Since the number of human cases has been rising and outbreaks are reappearing in a variety of countries after years of quiescence, the plague is considered a reemerging disease.[4, 5, 2] One reason may be the climatic change brought about by global warming, which is ideal for increasing the prevalence of Ypestis in the host population. One study has estimated a more than 50% increase in the plague host prevalence with an increase of 1 degree Centigrade of the temperature in spring. Another reason may be the increasing population explosion worldwide, which is bringing humans into ever-increasing contact with wildlife. Lastly, the dramatic population increase will contribute to conditions of overcrowding and poor sanitation—conditions ripe for plague hosts and vectors to flourish in.
Additionally, there has been significant concern over the return of plague as a potential biological weapon.[7, 8, 9] In 1347, the Tartars catapulted bodies of plague victims over the city walls during the siege of Kaffa, and, in World War II, the Japanese dropped bombs containing fleas inoculated with Yersinia pestis to infect their enemies with the deadly illness. During the Cold War, the Soviets succeeded in aerosolizing the bacteria and in creating strains of multidrug-resistant Yersinia.[10, 11] Aerosolized Y pestis, causing primary pneumonic plague, has been recognized by bioterrorism experts as having one of the highest potentials as a bioterrorism agent due to its extremely high mortality, its high uptake into enzootic and epizootic animals as well as humans, and its ability to be spread over a large area. It has been classified as a Category A, or high priority, bioterroism agent by the CDC. Biosafety level 3 precautions must be observed for any cultured specimens.
The etiologic agent of the plague is Y pestis, a facultative anaerobic, intracellular, gram-negative bacillus. Significant genomic similarity and conservation of DNA sequences suggest Y pestis evolved from the less virulent Yersinia pseudotuberculosis.
The organism can be transmitted from a host to a human via the bite of a vector (usually a flea), via close contact with infected tissue or body fluids, and via direct inhalation of aerosolized bacteria. Currently, the most common form of transmission involves the bite of an infected flea. More than 200 different rodents and species can serve as hosts.
The vector is usually the rat flea, Xenopsylla cheopis. Thirty different flea species have been identified as able to carry the plague bacillus. Other carriers of plague include ticks and human lice. A flea is shown in the image below.
Rodents resistant to the infection, such as wood rats, kangaroo roots, deer mice, grasshopper mice, and voles, form an enzootic stage that ensures the long-term survival of the bacillus. Occasionally, fleas transfer the bacteria to animals that are susceptible to plague such as ground squirrels (an infected squirrel is shown in the image below), prairie dogs, and chipmunks. In the event of large numbers of host animals dying off, hungry fleas search out new food sources. This is known as an epizootic stage and ensures the spread of the organism to new territory. A sylvatic stage occurs when humans are infected from wild animals. Carnivores with the exception of cats and black-footed ferrets have a fairly strong resistance profile, but they can be transfer vectors. Birds and hoofed animals are seldom infected, and reptiles and fish are resistant to plague.
Virulent plague bacteria can survive dormant in soil, animal carcasses, grains, flea feces, buried bodies, and dried sputum.[14, 3]
Three forms of the plague exist: bubonic plague, pneumonic plague, and septicemic plague. The bubonic form makes up approximately 80-95% of cases worldwide and is caused by deposition of the bacillus in the skin by the bite of an infected vector. If the vector is a flea, bacillus proliferates in the flea's esophagus, preventing food entry into the stomach. To overcome starvation, the flea begins a blood-sucking rampage. Between its attempts to swallow, the distended bacillus-packed esophagus recoils, depositing the bacillus into the victim's skin.
The bacillus invades nearby lymphoid tissue, producing the famous bubo, an inflamed, necrotic, and hemorrhagic lymph node. Spread occurs along the lymphatic channels toward the thoracic duct, with eventual seeding of the vasculature. Bacteremia and septicemia ensue. The bacillus potentially seeds every organ, including the lungs, liver, spleen, kidneys, and rarely even the meninges.
The most virulent form, pneumonic plague, results from direct inhalation of the bacillus, which occurs from close contact of infected hosts or from aerosolized bacteria such as may occur if used as a biological weapon. A severe and rapidly progressive multilobar bronchopneumonia ensues with subsequent bacteremia and septicemia. Secondary pneumonic plague is caused when an infected patient seeds his or her lungs and airways.
The third type of plague is a primary septicemic plague. This is hypothesized to occur when the bacillus is deposited in the vasculature, bypassing the lymphatics. Early dissemination with sepsis occurs but without the formation of a bubo. This usually is observed in bites to the oral, tonsillar, and pharyngeal area and is believed to occur because of the vascularity of the tissue and short lymphatic distance to the thoracic duct.
An average of seven (range, 1-17) human plague cases have been reported each year in the United States in recent decades. One of the largest animal foci of the plague worldwide is found west of the 100th parallel, in states such as New Mexico, Arizona, Colorado, Utah, and California. Only one case of imported plague has been reported since 1926. Most cases occur during the wet, warmer months of the year. However worldwide, between 1987 and 2001, according to the WHO, 36,876 cases of plague with 2847 deaths were reported. ref 50
Worldwide, plague occurs within a broad belt in tropical, subtropical, and warmer temperate climates (see the image below). Its geographical distribution coincides with that of the rodents it infects, which are found on all continents except Australia. Plague epidemics have occurred in Africa, Asia, and South America but since the 1990s, most human cases have occurred in Africa. The three most endemic countries are Madagascar, the Democratic Republic of Congo and Peru.
According to the World Health Organization, 783 cases of plague were reported worldwide in 2013, with 126 deaths. The actual number of cases is likely much higher, however. Almost all of the cases reported in the last 2 decades have been in inhabitants of small towns and villages or agricultural areas rather than in larger towns and cities.
Mortality from plague varies by type and treatment, as follows:
Bubonic plague has a 1-15% mortality rate in treated cases and a 40-60% mortality rate in untreated cases.
Septicemic plague (primary or secondary) has a 40% mortality rate in treated cases and 100% mortality rate in untreated cases.
Pneumonic plague (primary or secondary) has 100% mortality rate if not treated within the first 24 hours of infection.
Sex- and Age-related Demographics
More than 50% of cases of plague occur in males, probably because of greater participation in outdoor activities. Approximately 50% of cases occur in persons younger than 20 years.
Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am. 2008 May. 26(2):517-47, x-xi. [Medline].
Prentice MB, Rahalison L. Plague. Lancet. 2007 Apr 7. 369(9568):1196-207. [Medline].
Casman EA, Fischhoff B. Risk communication planning for the aftermath of a plague bioattack. Risk Anal. 2008 Oct. 28(5):1327-42. [Medline].
Joshi K, Thakur JS, Kumar R, Singh AJ, Ray P, Jain S, et al. Epidemiological features of pneumonic plague outbreak in Himachal Pradesh, India. Trans R Soc Trop Med Hyg. 2009 May. 103(5):455-60. [Medline].
Stenseth NC, Samia NI, Viljugrein H, Kausrud KL, Begon M, Davis S, et al. Plague dynamics are driven by climate variation. Proc Natl Acad Sci U S A. 2006 Aug 29. 103(35):13110-5. [Medline].
Christian MD. Biowarfare and bioterrorism. Crit Care Clin. 2013 Jul. 29(3):717-56. [Medline].
Abraham RT, Walls RT, Fischer M, Markovic-Reed S, Solovieva TI, Russell FK, et al. Tabletop scenarios for realism in bioterrorism and threat preparedness. W V Med J. 2012 Nov-Dec. 108(6):12-7. [Medline].
Wray RJ, Harris JK, Jupka K, Vijaykumar S, Mitchell EW, Pollard W, et al. Individual and community influences on adherence to directives in the event of a plague attack: survey results. Disaster Med Public Health Prep. 2012 Oct. 6(3):253-62. [Medline].
Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun. 2008 Aug. 76(8):3808-16. [Medline]. [Full Text].
Werner SB, Weidmer CE, Nelson BC, Nygaard GS, Goethals RM, Poland JD. Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, Calif. JAMA. 1984 Feb 17. 251(7):929-31. [Medline].
Ayyadurai S, Houhamdi L, Lepidi H, Nappez C, Raoult D, Drancourt M. Long-term persistence of virulent Yersinia pestis in soil. Microbiology. 2008 Sep. 154:2865-71. [Medline].
Plague. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/plague/maps/. Accessed: July 20, 2015.
World Health Organization. Plague: Fact Sheet No. 267. WHO. Available at http://www.who.int/mediacentre/factsheets/fs267/en/. November 2014; Accessed: July 20, 2015.
Chanteau S, Rahalison L, Ratsitorahina M, Mahafaly, Rasolomaharo M, Boisier P, et al. Early diagnosis of bubonic plague using F1 antigen capture ELISA assay and rapid immunogold dipstick. Int J Med Microbiol. 2000 Jul. 290 (3):279-83. [Medline].
Galiman M, Carniel E, Courvalin P. Resistence of Yersinia pestis to Antimicrobial Agents. Antimicrobial Agents and Chemotherapy. 2006. 50:3233-3236.
Waterer GW, Robertson H. Bioterrorism for the respiratory physician. Respirology. 2009 Jan. 14(1):5-11. [Medline].
Barnes AM, Quam TJ. Plague. Gorbach SL, Bartlett JG, Balacklow NR, eds. Infectious Diseases. 1992. 1285-91.
Branda JA, Ruoff K. Bioterrorism. Clinical recognition and primary management. Am J Clin Pathol. 2002 Jun. 117 Suppl:S116-23. [Medline].
Burmeister RW, Tigertt WD, Overholt EL. Laboratory-acquired pneumonic plague. Report of a case and review of previous cases. Ann Intern Med. 1962 May. 56:789-800. [Medline].
Butler T. Yersinia species (including plagues). Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. 1990.
Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, Ratsifasoamanana L. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet. 2003 Jan 18. 361(9353):211-6. [Medline].
Christie AB, Corbel MS. Topley and Wilson, eds. Principles of Bacteriology, Virology and Immunity. 3rd-8th ed. 1990. 400-9.
Conner C. Plague. Pathology of Infectious Diseases. 1997. 729-38.
Connor JD, Williams RA, Thompson MA, et al. Plague in San Diego [clinical conference]. West J Med. 1978 Nov. 129(5):394-406. [Medline].
Craven RB, Maupin GO, Beard ML, et al. Reported cases of human plague infections in the United States, 1970- 1991. J Med Entomol. 1993 Jul. 30(4):758-61. [Medline].
Crook LD, Tempest B. Plague. A clinical review of 27 cases. Arch Intern Med. 1992 Jun. 152(6):1253-6. [Medline].
Hoffman SL. Plague in the United States: the "black death" is still alive. Ann Emerg Med. 1980 Jun. 9(6):319-22. [Medline].
Hull HF, Montes JM, Mann JM. Septicemic plague in New Mexico. J Infect Dis. 1987 Jan. 155(1):113-8. [Medline].
Humphrey M, McGivney R, Perkins C, Harris R, Rowe J. Yersinia pestis: a case of mistaken identity. Pediatr Infect Dis J. 1988 May. 7(5):365-6. [Medline].
Koirala J. Plague: disease, management, and recognition of act of terrorism. Infect Dis Clin North Am. 2006 Jun. 20(2):273-87, viii. [Medline].
Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis. 2005 Apr 15. 40(8):1166-72. [Medline].
Lazarus AA, Decker CF. Plague. Respir Care Clin N Am. 2004 Mar. 10(1):83-98. [Medline].
Leopold JC. Septicemic plague in a 14-month-old child. Pediatr Infect Dis. 1986 Jan-Feb. 5(1):108-10. [Medline].
Mann JM, Hull HF, Schmid GP, Droke WE. Plague and the peripheral smear. JAMA. 1984 Feb 17. 251(7):953. [Medline].
Marcus LC. Wilderness acquired zoonoses. Auerbach PS, Geehr EC, eds. Management of Wilderness and Environmental Emergencies. 1989.
McGovern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol. 1999 Mar. 135(3):311-22. [Medline].
McGovern TW, Friedlander AM. Plague. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Sidell FR, Takafuji ET, Franz DR, Zajtchuk R, Bellamy RF, eds. eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Textbook of Military Medicine. Office of the Surgeon General of the Army; 1997. 479-502.
Mwengee W, Butler T, Mgema S, Mhina G, Almasi Y, Bradley C. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis. 2006 Mar 1. 42(5):614-21. [Medline].
Navas E. Problems associated with potential massive use of antimicrobial agents as prophylaxis or therapy of a bioterrorist attack. Clin Microbiol Infect. 2002 Aug. 8(8):534-9. [Medline].
Outbreak news. Plague, Democratic Republic of the Congo. Wkly Epidemiol Rec. 2006 Oct 20. 81(42):397-8. [Medline].
Perry RD, Fetherston JD. Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev. 1997 Jan. 10(1):35-66. [Medline].
Rollins SE, Rollins SM, Ryan ET. Yersinia pestis and the plague. Am J Clin Pathol. 2003 Jun. 119 Suppl:S78-85. [Medline].
Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002 Feb. 8(2):225-30. [Medline].
Welty TK, Grabman J, Kompare E, et al. Nineteen cases of plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in pregnancy. West J Med. 1985 May. 142(5):641-6. [Medline].
Human Plague in 200 and 2001. Wkyl Epidemiol Rec. 2003. 78:130-135.